134 related articles for article (PubMed ID: 38364881)
1. Successful treatment approaches for tumoral calcinosis in children and young people: A condition of diverse pathogenesis.
Anilkumar A; Högler W; Bursell J; Nadar R; Ryan F; Randell T; Shaw NJ; Uday S
Bone; 2024 May; 182():117049. PubMed ID: 38364881
[TBL] [Abstract][Full Text] [Related]
2. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Finer G; Price HE; Shore RM; White KE; Langman CB
Am J Med Genet A; 2014 Jun; 164A(6):1545-9. PubMed ID: 24668887
[TBL] [Abstract][Full Text] [Related]
3. Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma.
Iwasaki H
Endocrinol Diabetes Metab Case Rep; 2023 Oct; 2023(4):. PubMed ID: 37787752
[TBL] [Abstract][Full Text] [Related]
4. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
Ito N; Fukumoto S
Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
[TBL] [Abstract][Full Text] [Related]
5. The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in
Döneray H; Özden A; Gürbüz K
J Clin Res Pediatr Endocrinol; 2022 Jun; 14(2):239-243. PubMed ID: 33685073
[TBL] [Abstract][Full Text] [Related]
6. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
Lammoglia JJ; Mericq V
Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
[TBL] [Abstract][Full Text] [Related]
7. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.
Boyce AM; Lee AE; Roszko KL; Gafni RI
Front Endocrinol (Lausanne); 2020; 11():293. PubMed ID: 32457699
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.
Zuo QY; Cao X; Liu BY; Yan D; Xin Z; Niu XH; Li C; Deng W; Dong ZY; Yang JK
J Endocrinol Invest; 2020 Feb; 43(2):173-183. PubMed ID: 31535357
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
[TBL] [Abstract][Full Text] [Related]
11. Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.
Sowaity ZA; Saleem JY; Sabooh TN; Dukmak ON; Abu Al-Saoud SY
Cureus; 2024 Mar; 16(3):e55575. PubMed ID: 38576700
[TBL] [Abstract][Full Text] [Related]
12. Primary hyperphosphatemic tumoral calcinosis: a case report.
Huang J; Cao LG; Zhang TR; Li SM; Meng QQ
Osteoporos Int; 2022 Jan; 33(1):309-312. PubMed ID: 34245344
[TBL] [Abstract][Full Text] [Related]
13. Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate.
Emecen Sanli M; Kilic A; Aktasoglu E; Inci A; Okur I; Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):813-816. PubMed ID: 33819418
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
15. A novel
Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
[TBL] [Abstract][Full Text] [Related]
16. Familial tumoral calcinosis.
Alkhatib A; Burton LE; Carachi R
Scott Med J; 2014 Nov; 59(4):e17-20. PubMed ID: 25351424
[TBL] [Abstract][Full Text] [Related]
17. Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Liu C; Pang Q; Jiang Y; Xia Y; Fang L; Wang O; Li M; Xing X; Gong Y; Xia W
Bone; 2020 Aug; 137():115401. PubMed ID: 32360901
[TBL] [Abstract][Full Text] [Related]
18. Bone Involvement in Hyperphosphatemic Familial Tumoral Calcinosis: A New Phenotypic Presentation.
Freedman JD; Novak R; Bratman Morag S; Avitan-Hersh E; Nikomarov D
Rambam Maimonides Med J; 2021 Jul; 12(3):. PubMed ID: 34270404
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
